6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Great Controversy of Obstructive Sleep Apnea Treatment for Cardiovascular Risk Benefit: Advancing the Science through Expert Consensus: An Official American Thoracic Society Workshop Report

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Annals of the American Thoracic Society
      American Thoracic Society
      obstructive sleep apnea, positive airway pressure therapy, cardiovascular disease outcomes, health equity

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The prevalence of obstructive sleep apnea (OSA) is on the rise, driven by various factors, including more sensitive diagnostic criteria, increased awareness, enhanced technology through at-home testing enabling easy and cost-effective diagnosis, and a growing incidence of comorbid conditions such as obesity. Treating symptomatic patients with OSA syndrome to enhance quality of life remains a cornerstone approach. However, there is a lack of consensus regarding treatment to improve cardiovascular disease (CVD) outcomes, particularly in light of overall negative results from several randomized controlled trials indicating no benefit of positive airway pressure therapy on primary and secondary CVD events. These randomized controlled trials were limited by suboptimal positive airway pressure adherence, use of composite CVD outcomes, and limited diversity and generalizability to sleep clinic patients. As such, this workshop assembled clinical experts, as well as researchers in basic and translational science, epidemiology, clinical trials, and population health, to discuss the current state and future research directions to guide personalized therapeutic strategies and future research directions in OSA. There was overall consensus among workshop participants that OSA represents a heterogeneous disease with variable endotypes and phenotypes and heterogeneous responses to treatment. Future research should prioritize using multimodal therapeutic approaches within innovative and adaptive trial designs, focusing on specific subgroups of patients with OSA hypothesized to benefit from a CVD perspective. Future work should also be inclusive of diverse populations and consider the life course of OSA to better comprehend treatment strategies that can address the disproportionate impact of OSA on racially minoritized groups. Furthermore, a more holistic approach to sleep must be adopted to include broader assessments of symptoms, sleep duration, and comorbid sleep and circadian disorders. Finally, it is imperative to establish a sleep research consortium dedicated to collecting raw data and biospecimens categorized by OSA subtypes. This will facilitate mechanistic determinations, foster collaborative research, and help bolster the pipeline of early-career researchers.

          Related collections

          Most cited references167

          • Record: found
          • Abstract: found
          • Article: not found

          Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis

          There is a scarcity of published data on the global prevalence of obstructive sleep apnoea, a disorder associated with major neurocognitive and cardiovascular sequelae. We used publicly available data and contacted key opinion leaders to estimate the global prevalence of obstructive sleep apnoea.
            • Record: found
            • Abstract: not found
            • Article: not found

            Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association

              • Record: found
              • Abstract: found
              • Article: not found

              Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

              The effect of obstructive sleep apnoea-hypopnoea as a cardiovascular risk factor and the potential protective effect of its treatment with continuous positive airway pressure (CPAP) is unclear. We did an observational study to compare incidence of fatal and non-fatal cardiovascular events in simple snorers, patients with untreated obstructive sleep apnoea-hypopnoea, patients treated with CPAP, and healthy men recruited from the general population. We recruited men with obstructive sleep apnoea-hypopnoea or simple snorers from a sleep clinic, and a population-based sample of healthy men, matched for age and body-mass index with the patients with untreated severe obstructive sleep apnoea-hypopnoea. The presence and severity of the disorder was determined with full polysomnography, and the apnoea-hypopnoea index (AHI) was calculated as the average number of apnoeas and hypopnoeas per hour of sleep. Participants were followed-up at least once per year for a mean of 10.1 years (SD 1.6) and CPAP compliance was checked with the built-in meter. Endpoints were fatal cardiovascular events (death from myocardial infarction or stroke) and non-fatal cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, coronary artery bypass surgery, and percutaneous transluminal coronary angiography). 264 healthy men, 377 simple snorers, 403 with untreated mild-moderate obstructive sleep apnoea-hypopnoea, 235 with untreated severe disease, and 372 with the disease and treated with CPAP were included in the analysis. Patients with untreated severe disease had a higher incidence of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) than did untreated patients with mild-moderate disease (0.55, p=0.02 and 0.89, p<0.0001), simple snorers (0.34, p=0.0006 and 0.58, p<0.0001), patients treated with CPAP (0.35, p=0.0008 and 0.64, p<0.0001), and healthy participants (0.3, p=0.0012 and 0.45, p<0.0001). Multivariate analysis, adjusted for potential confounders, showed that untreated severe obstructive sleep apnoea-hypopnoea significantly increased the risk of fatal (odds ratio 2.87, 95%CI 1.17-7.51) and non-fatal (3.17, 1.12-7.51) cardiovascular events compared with healthy participants. In men, severe obstructive sleep apnoea-hypopnoea significantly increases the risk of fatal and non-fatal cardiovascular events. CPAP treatment reduces this risk.

                Author and article information

                Contributors
                On behalf of : on behalf of the American Thoracic Society Assembly on Sleep and Respiratory Neurobiology
                Journal
                Ann Am Thorac Soc
                Ann Am Thorac Soc
                AnnalsATS
                Annals of the American Thoracic Society
                American Thoracic Society
                2329-6933
                2325-6621
                1 January 2025
                1 January 2025
                1 January 2025
                : 22
                : 1
                : 1-22
                Author notes
                Correspondence and requests for reprints should be addressed to Neomi Shah, M.D., M.P.H., M.S.C., Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1232, New York, NY 10029. E-mail: neomi.shah@ 123456mssm.edu .
                [*]

                Workshop co-chairs

                Author information
                https://orcid.org/0009-0004-2827-9063
                https://orcid.org/0000-0002-2923-9539
                https://orcid.org/0000-0002-2340-8928
                https://orcid.org/0000-0001-9067-6538
                https://orcid.org/0000-0002-5695-348X
                https://orcid.org/0000-0001-8812-8751
                https://orcid.org/0000-0003-0488-9778
                https://orcid.org/0000-0003-0686-3520
                https://orcid.org/0000-0001-8195-6036
                https://orcid.org/0000-0003-0849-3391
                https://orcid.org/0000-0003-4045-4341
                https://orcid.org/0000-0002-0915-8272
                https://orcid.org/0000-0002-1278-6245
                https://orcid.org/0000-0002-9142-5172
                Article
                202409-981ST
                10.1513/AnnalsATS.202409-981ST
                11708754
                39513996
                625beb41-5685-443b-9296-dd8e5d412dce
                Copyright © 2025 by the American Thoracic Society

                You may print one copy of this document at no charge. However, if you require more than one copy, you must place a reprint order. Domestic reprint orders: amy.schriver@ 123456sheridan.com ; international reprint orders: louisa.mott@ 123456springer.com .

                History
                Page count
                Figures: 3, Tables: 2, References: 167, Pages: 22
                Categories
                American Thoracic Society Documents

                obstructive sleep apnea,positive airway pressure therapy,cardiovascular disease outcomes,health equity

                Comments

                Comment on this article

                Related Documents Log